Phase 2 Large B-cell Lymphoma Clinical Trials
93 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 93 trials
Recruiting
Phase 2
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Diffuse Large B-Cell Lymphoma+12 more
National Cancer Institute (NCI)120 enrolled84 locationsNCT06649812
Recruiting
Phase 2
Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy
Recurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell LymphomaRecurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma+1 more
University of California, Davis34 enrolled1 locationNCT06854159
Recruiting
Phase 1Phase 2
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Mantle Cell LymphomaSmall Lymphocytic LymphomaB-cell Non Hodgkin Lymphoma+2 more
AstraZeneca408 enrolled64 locationsNCT06564038
Recruiting
Phase 2
A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T
Large B-cell Lymphoma
University Health Network, Toronto76 enrolled1 locationNCT06167785
Recruiting
Phase 2
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
High-grade B-cell LymphomaDiffuse Large B-Cell Lymphoma (DLBCL)
Memorial Sloan Kettering Cancer Center42 enrolled8 locationsNCT06765317
Recruiting
Phase 1Phase 2
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Diffuse Large B-Cell Lymphoma+11 more
Yazeed Sawalha38 enrolled2 locationsNCT06536049
Recruiting
Phase 2
Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse
Refractory High Grade B-Cell LymphomaRefractory Transformed B-cell Non-Hodgkin LymphomaDiffuse Large B Cell Lymphoma Refractory+1 more
The Lymphoma Academic Research Organisation65 enrolled13 locationsNCT06271057
Recruiting
Phase 2
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Large B-cell Lymphoma
Allogene Therapeutics250 enrolled73 locationsNCT06500273
Recruiting
Phase 2
Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)
Relapsed or Refractory Large B-cell Lymphoma
University of Utah29 enrolled1 locationNCT06788964
Recruiting
Phase 1Phase 2
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaLarge B-cell Lymphoma+1 more
Lyell Immunopharma, Inc.270 enrolled34 locationsNCT05826535
Recruiting
Phase 2
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
High-grade B-cell LymphomaLymphoma, Non-HodgkinRefractory Diffuse Large B-Cell Lymphoma+2 more
Abramson Cancer Center at Penn Medicine31 enrolled1 locationNCT06458439
Recruiting
Phase 2
CAR-T Followed by Bispecific Antibodies
DLBCL - Diffuse Large B Cell LymphomaLarge B-cell Lymphoma
Abramson Cancer Center at Penn Medicine23 enrolled2 locationsNCT04889716
Recruiting
Phase 2
Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes
Diffuse Large B-Cell Lymphoma (DLBCL)
The First Affiliated Hospital with Nanjing Medical University35 enrolled1 locationNCT07608978
Recruiting
Phase 2
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
LymphomaLarge B-cell Lymphoma
M.D. Anderson Cancer Center30 enrolled1 locationNCT05464719
Recruiting
Phase 2
Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
Large B-cell Lymphoma
M.D. Anderson Cancer Center40 enrolled1 locationNCT06045247
Recruiting
Phase 2
Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden
LymphomaRelapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Liling Zhang40 enrolled1 locationNCT06867536
Recruiting
Phase 2
Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies
Recurrent Follicular LymphomaRefractory Follicular LymphomaRecurrent B-Cell Non-Hodgkin Lymphoma+5 more
University of Washington20 enrolled1 locationNCT05453396
Recruiting
Phase 2
Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Recurrent Transformed Chronic Lymphocytic LeukemiaRefractory Transformed Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell Lymphoma+9 more
City of Hope Medical Center36 enrolled1 locationNCT05672251
Recruiting
Phase 2
The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL
Large B-Cell Lymphoma (LBCL)
Ruijin Hospital30 enrolled1 locationNCT07514169
Recruiting
Phase 2
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
Recurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell LymphomaRecurrent High Grade B-Cell Lymphoma+9 more
University of Washington27 enrolled1 locationNCT06784726